Literature DB >> 25243015

High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa.

Sarita Naidoo1, Handan Wand2, Nathlee Samantha Abbai1, Gita Ramjee3.   

Abstract

BACKGROUND AND OBJECTIVES: Sexually transmitted infections (STIs) contribute largely to the burden of health in South Africa and are recognized as major contributors to the human immunodeficiency virus (HIV) epidemic. Young women are particularly vulnerable to STIs. The purpose of this secondary analysis was to examine the risk factors associated with prevalent and incident STIs among women who had participated in three clinical trials.
METHODS: A total of 5,748 women were screened and 2293 sexually active, HIV negative, non-pregnant women were enrolled in three clinical trials in Kwazulu-Natal, South Africa. The prevalence of individual STIs Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), syphilis, and Trichomonas vaginalis (TV) was assessed at screening; and incident infections were evaluated over a 24 month period.
RESULTS: Overall, the combined study population of all three trials had a median age of 28 years (inter-quartile range (IQR):22-37), and a median duration of follow-up of 12 months. Prevalence of STIs (CT, NG, TV, or syphilis) was 13% at screening. The STI incidence was estimated to be 20/100 women years. Younger women (<25 years, p < 0.001), women who were unmarried (p < 0.001) and non-cohabiting women (p < 0.001) were shown to be at highest risk for incident STIs.
CONCLUSIONS: These results confirm the extremely high prevalence and incidence of STIs among women living in rural and urban communities of KwaZulu-Natal, South Africa, where the HIV epidemic is also particularly severe. These findings strongly suggest an urgent need to allocate resources for STI and HIV prevention that mainly target younger women. TRIAL REGISTRATION: Clinical Trials.gov, NCT00121459.

Entities:  

Keywords:  HIV; Incidence; Kwa-Zulu Natal; Prevalence; Risk factors; Sexually transmitted infections; Women

Year:  2014        PMID: 25243015      PMCID: PMC4168991          DOI: 10.1186/1742-6405-11-31

Source DB:  PubMed          Journal:  AIDS Res Ther        ISSN: 1742-6405            Impact factor:   2.250


Introduction

South Africa (SA) is at the epicenter of the human immunodeficiency virus (HIV) epidemic; and other sexually transmitted infections (STIs) continue to be endemic [1-3]. STIs have been associated with pelvic inflammatory disease, adverse pregnancy outcomes, cervical cancer, infertility, and multiple reproductive tract sequelae [4]. Furthermore, the evidence that STIs facilitate HIV acquisition and transmission [5,6] enhances the seriousness of the problem. KwaZulu-Natal (KZN), the most densely populated province in SA, has been markedly affected by both the HIV and STI epidemic [7,1]; with a disproportionate burden of STIs and HIV among women. Several studies conducted within various populations of women in KZN have shown high prevalence of HIV coupled with STIs [8-11]. Control of STIs therefore remains extremely important in these high risk populations. Availability of data on the epidemiology of STIs and associated risk factors in these populations is thus essential for the development of successful targeted interventions in this region. This study presents combined data from a large cohort of women, from urban and rural areas of KZN, who participated in three clinical trials; to determine the prevalence and incidence of STIs [(Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), syphilis, and Trichomonas vaginalis (TV)] and the associated risk factors. This data provides an opportunity to gain further insights into the overall STI prevalence and incidence in this region; and will inform the design of future HIV/STI prevention strategies by identifying and defining populations most at risk.

Methods

Study population

This analysis includes women who participated in three multi-centre trials at sites in KZN: Methods for Improving Reproductive Health in Africa (MIRA) trial [12], conducted in rural Umkomaas and Botha’s Hill; Microbicides Development Programme (MDP) Feasibility study in preparation for Phase III Microbicide Trials [13], in semi-rural Tongaat and Verulam; and HIV Prevention Trials Network (HPTN) Site Preparedness study (HPTN 055) for future implementation of Phase 2/IIb/III HIV Prevention Studies [14], in an urban area in Durban and in a rural district of Hlabisa. Study populations were described elsewhere in detail [12-14].

Study procedures

Study procedures were described in detail elsewhere [12-14]. Main inclusion criteria were similar in all three studies, and briefly included being sexually active; HIV negative at screening; not pregnant, willing to provide written consent, and follow study procedures. Information on demographics and sexual behaviors were collected. Participants received risk reduction counseling and condoms; and treatment was provided for curable, symptomatic or laboratory-diagnosed STIs. Women diagnosed as HIV-positive were referred to local health care facilities for further care and support. Male partners were encouraged to access the trial sites for counseling, HIV testing and STI treatment. Additionally, women diagnosed with STIs were given referrals for their partners to access treatment at local clinics. Study protocols and informed consent forms were approved by the local ethics committee and various Institutional Review Boards.

Laboratory procedures

STI and HIV testing was described previously for each study [12,15,16]. Briefly, in the MIRA trial, [16] CT, GC and TV were detected by PCR (Roche Pharmaceuticals, Branchburg, NJ, USA) and syphilis by rapid plasma reagin (RPR) and Treponema pallidum haemagglutinin (TPHA) (Randox Laboratories, Crumlin, UK). In HPTN 055 [15], CT and GC were detected using the BDProbe Tec ET assay (Becton Dickinson, MD), TV by wet mount microscopy and syphilis by RPR and confirmatory TPHA. In MDP Feasibility [16], CT and GC were detected using PCR (COBAS Amplicor, Roche Molecular Diagnostics, Pleasanton, CA, USA), TV by wet mount microscopy and syphilis by RPR and confirmatory TPHA (Omega Diagnostics, Alva, UK).

Statistical analysis

Differences in proportions were tested using the chi-square test. The Student’s t test was used to compare averages. Univariate and multivariate logistic regression analyses were conducted to identify variables predictive of any STI (CT, NG, TV or Syphilis) infection at screening. Only variables determined to be consistent across the studies were included. STI incidence was determined as the first positive test after a negative test at enrollment. Associations between various factors and STI incidence were described using Kaplan-Meier survival plots and log-rank tests. Risk factors for STI incidence were assessed using Cox proportional hazard regression models. Multivariate models considered all variables statistically significant (p < 0.05) in initial analyses and used forward stepwise methods. Statistical analysis was performed using STATA Release 8.2 (Stata Statistical Software: Stata Corporation, College Station, Texas, USA).

Results

Of the 5,748 women screened, 3492 were from the MIRA trial, 1221 from MDP Feasibility; and 1035 from HPTN055. Overall, the women had a median age of 28 years (inter-quartile range (IQR):22–37), and a median duration of follow-up of 12 months (data not shown). Majority were from rural areas (91%); unmarried (85%); and not living with regular sexual partners (non-cohabiting) (68%). Over half (53%) reported less than high school education. HIV and STI (diagnosed with at least one STI: CT, NG, TV or syphilis) prevalence at baseline was 42% (2407/5748) and 13% (738/5748), respectively.

Risk factors for STIs at screening

Women with prevalent STIs (≥1) were younger (<25 years) (p < 0.001); reported less than high school education (p < 0.0001), were unmarried (p < 0.0001); and non-cohabiting (p < 0.0001) (Table 1). Table 2 shows that women who were HIV positive, <25 years of age; unmarried; non- cohabiting; and who reported less than high school education were significantly associated with increased risk of having a prevalent STI (Odds Ratios (OR):1.50, 95% Confidence Intervals (CI):1.27-1.76; OR:1.36, 95% CI:1.11-1.68; OR:1.60, 95% CI:1.14-2.24; OR:1.27,95% CI:1.03-1.60; and OR:1.75, 95% CI:1.49-2.06 respectively).
Table 1

Demographic variables by STI status at screening

VariablesOverall
STI+
STI-
p-value
N = 5,748 (%)N = 728 (%)N = 5,020 (%)
HIV prevalence at screening
2,407 (42)
375 (52)
2,032 (40)
<0.001
District
 
 
 
0.524
Rural
5216 (91)
656 (90)
4560 (91)
 
Urban
532 (9)
72 (10)
460 (9)
 
Age, mean (SD)
28.6 (8)
26 (7)
29 (8)
 
Age groups (years)
 
 
 
 
≤ 24
2,223 (39)
367 (50)
1856 (37)
<0.001
25-34
2,224 (39)
255 (35)
1969 (39)
 
35+
1,305 (22)
106 (15)
1199 (24)
 
Education
 
 
 
 
Less than high school
3069 (53)
467 (61)
2602 (52)
<0.0001
Marital status
 
 
 
 
Not married
4,912 (85)
677 (93)
4235 (84)
<0.0001
Co-habitation status
 
 
 
 
Non-cohabiting3,929 (68)566 (78)3363 (70)<0.0001

†Diagnosis of chlamydia, gonorrhea, trichomonas or syphilis.

‡Hlabisa, Umkomaas, Botha’s Hill, Tongaat and Verulam.

ᆕDurban.

Table 2

Risk factors for being diagnosed with STI at screening: results from univariate and multivariate logistic regression models

VariableUnivariate analysis
p-valueMultivariate analysis
p-value
OR (95% CI)OR (95% CI)
HIV infection status
 
 
 
 
HIV negative
1
 
1
 
HIV positive
1.56 (1.34-1.83)
<0.0001
1.50 (1.27-1.76)
<0.0001
Age (years)
 
 
 
 
<25
1.60 (1.33-1.92)
0.000
1.36 (1.11-1.68)
0.003
25 - 34
1.17 (0.95-1.43)
0.137
1.08 (0.87-1.34)
0.480
35+
1
-
1
-
Education
 
 
 
 
Less than high school
1.67 (1.42-1.96)
<0.00001
1.75 (1.49-2.06)
<0.0001
Marital status
 
 
 
 
Not married
2.47 (1.84-3.32)
<0.0001
1.60 (1.14-2.24)
0.006
Co-habitation status
 
 
 
 
Non-cohabiting1.73 (1.43-2.07)<0.00011.27 (1.03-1.60)0.024

CI, confidence interval; OR, odds ratio.

Demographic variables by STI status at screening †Diagnosis of chlamydia, gonorrhea, trichomonas or syphilis. ‡Hlabisa, Umkomaas, Botha’s Hill, Tongaat and Verulam. ᆕDurban. Risk factors for being diagnosed with STI at screening: results from univariate and multivariate logistic regression models CI, confidence interval; OR, odds ratio.

Incidence of STIs

Crude STI incidence amongst the 2293 enrolled women was 680 (20/100 women-years). Kaplan-Meier survival curves of infection stratified by age, marital, and co-habitation status are shown in Figure 1a-c. The highest incidence rate was observed for women <25 years old (26/100 women-years, p < 0.001), followed by moderately high incidence rates for unmarried and non-cohabiting women (22/100 women-years, p < 0.001 and 21/100 women-years, p < 0.001; respectively).
Figure 1

The Kaplan-Meier survival curves of STI incidence stratified by age (a), marital status (b) and cohabitation status (c).

The Kaplan-Meier survival curves of STI incidence stratified by age (a), marital status (b) and cohabitation status (c). Table 3 shows that baseline STI infection, being <25 years of age; unmarried; and non-use of contraception were significantly associated with increased risk of acquiring incident STIs (OR:1.52, 95% CI:1.22-1.88; OR:1.40, 95% CI:1.14-1.74; OR:1.54, 95% CI:1.22-1.94 and OR:1.40, 95% CI:1.19-1.64, respectively). No significant associations with incident STIs were observed for geographical area, employment status, condom use and education level.
Table 3

Risk factors for incidence of STI during follow up: results from cox regression models

VariableUnivariate analysis
p-valueMultivariate analysis
p-value
HR (95% CI)HR (95% CI)
Any STI at baseline
1.61 (1.30-2.00)
-
1.52 (1.22-1.88)
0.000
Age
 
 
 
 
≤25
1.64 (1.36-2.00)
<0.001
1.40 (1.14-1.74)
0.001
25-34
1.19 (0.97-1.46)
0.100
1.10 (0.89-1.37)
0.370
35+
1
-
 
 
District
 
 
 
 
Rural
0.93 (0.69-1.25)
0.628
-
 
Urban
1
-
 
 
Employed/income
 
 
 
 
No
1.35 (1.10-1.66)
0.0038
-
 
Yes
1
-
 
 
Level of education
 
 
 
 
High school or more
1
-
 
 
Less than high school
1.25 (1.06-1.46)
0.006
-
 
Contraceptive use
 
 
 
 
At least one form of contraceptive1
1
-
 
 
None
1.33 (1.13-1.55)
<0.001
1.40 (1.19-1.64)
0.000
Marital status
 
 
 
 
Married
1
-
 
 
Not married
1.84 (1.49-2.27)
<0.0001
1.54 (1.22-1.94)
0.000
Cohabitation status
 
 
 
 
Yes
1
-
 
 
No
1.43 (1.21-1.68)
<0.0001
-
 
Condom used during last sexual act
 
 
 
 
No
1.00 (0.86-1.16)
0.98
-
 
Yes1-  

CI, confidence interval; HR Hazard ratio.

1including condom, injectables, pills, traditional methods.

Risk factors for incidence of STI during follow up: results from cox regression models CI, confidence interval; HR Hazard ratio. 1including condom, injectables, pills, traditional methods.

Discussion

Our analysis confirms that STI prevalence and incidence is extremely high in women living in KZN. The prevalence of STIs was 13% while the incidence rate was 20/100 women-years. Similar STI incidence was reported in other studies conducted in SA [15,17-19]. Incidence of STIs in this cohort was unacceptably high despite provision of risk reduction counseling, condoms, treatment for curable STIs; and partner treatment or referral. In this study, women who were <25 years; unmarried; and non-cohabiting were identified as being at most risk for STI acquisition. Recent evidence from a PrEP trial, VOICE, conducted in SA, Zimbabwe and Uganda, showed the same risk factors associated with increased risk of HIV acquisition [20]. Similarly, Feldblum and colleagues [19] observed that younger age was associated with incident HIV and STIs. Another study also showed that younger women were at higher risk of acquiring new STIs [18]. Studies in Tanzania [21], Kenya [22] and Brazil [23] reported that being unmarried was associated with STI acquisition. Predictably, having an STI at baseline also placed women at increased risk of acquiring an STI during follow up, and at substantial risk of HIV acquisition. HIV infection at screening was associated with a significantly higher prevalence among women diagnosed with at least one STI compared to those who had no STI; providing further evidence for the relationship between HIV and STIs. Mlisana and colleagues [17] reported a similar finding. It was also previously suggested that HIV prevention efforts in SA may be enhanced by screening STI patients for acute HIV infection [6]. This study defined populations who are most at risk of STI acquisition and broadly showed the common risk factors associated with STI prevalence and incidence suggesting the need for effective behavioural or biomedical interventions. This data will aide in the design of future interventions in these populations; and contributes to the STI surveillance data for women in this region. Our study has several limitations. These results may not be representative of the wider population as these women were recruited from selected populations. However this large data set, together with the numerous STIs detected, provides valuable information on the STI epidemic in this region. Another limitation is the slight variations in testing methods used for STI diagnosis in the different trials, where some methods may have been more sensitive than others. Additionally, the risk factor analyses were restricted to socio-demographic and behavioral variables that were assessed consistently across all three studies, possibly resulting in reducing the power of the analyses to detect significant associations. Finally, although all STIs were treated, there was no information on partner infection status or resistant infections during follow up.

Conclusions

Due to the high incidence of STIs observed in this population, targeted interventions aimed at young women and their partners, are urgently needed. Control and treatment of STIs still remains an important public health priority for HIV prevention and should include a combination of prevention efforts such as extensive health education, condom promotion, male circumcision, and HIV and STI testing in all patient-provider encounters.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

GR and HW developed the concept. HW conducted the statistical analysis. SN wrote the manuscript with input from GR, HW and NSA. All authors read and approved the final manuscript.

Authors’ information

Handan Wand, Nathlee S Abbai, Gita Ramjee Co-authors.
  19 in total

1.  Classical sexually transmitted diseases drive the spread of HIV-1: back to the future.

Authors:  Myron S Cohen
Journal:  J Infect Dis       Date:  2012-04-19       Impact factor: 5.226

2.  Baseline factors associated with incident HIV and STI in four microbicide trials.

Authors:  Paul J Feldblum; Che-Chin Lie; Mark A Weaver; Lut Van Damme; Vera Halpern; Adesina Adeiga; Rashidi Bakare; Jill Schwartz; Marissa Becker; Suniti Solomon
Journal:  Sex Transm Dis       Date:  2010-10       Impact factor: 2.830

3.  Risk factors for sexually transmitted diseases among women attending family planning clinics in Dar-es-Salaam, Tanzania.

Authors:  D M Gertig; S H Kapiga; J F Shao; D J Hunter
Journal:  Genitourin Med       Date:  1997-02

4.  Sexually transmitted disease syndromes in rural South Africa. Results from health facility surveillance.

Authors:  D Wilkinson; A M Connolly; A Harrison; M Lurie; S S Karim
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

5.  Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.

Authors:  Koleka Mlisana; Nivashnee Naicker; Lise Werner; Lindi Roberts; Francois van Loggerenberg; Cheryl Baxter; Jo-Ann S Passmore; Anneke C Grobler; A Willem Sturm; Carolyn Williamson; Katharina Ronacher; Gerhard Walzl; Salim S Abdool Karim
Journal:  J Infect Dis       Date:  2012-04-19       Impact factor: 5.226

6.  The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa.

Authors:  Gita Ramjee; Brian Williams; Eleanor Gouws; Eddy Van Dyck; Bénédicte De Deken; Salim Abdool Karim
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

7.  Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study.

Authors:  Saidi Kapiga; Cliff Kelly; Stephen Weiss; Tara Daley; Leigh Peterson; Corey Leburg; Gita Ramjee
Journal:  Sex Transm Dis       Date:  2009-04       Impact factor: 2.830

8.  Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors.

Authors:  Valquíria de Lima Soares; Ana Maria Torres S de Mesquita; Fábia Gazzaneo T Cavalcante; Zenaldo Porfírio Silva; Valéria Hora; Thomas Diedrich; Patrícia de Carvalho Silva; Poliana Gomes de Melo; Alfredo Raimundo C Dacal; Eduardo Maia Freese de Carvalho; Hermann Feldmeier
Journal:  Trop Med Int Health       Date:  2003-07       Impact factor: 2.622

9.  Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.

Authors:  Nancy S Padian; Ariane van der Straten; Gita Ramjee; Tsungai Chipato; Guy de Bruyn; Kelly Blanchard; Stephen Shiboski; Elizabeth T Montgomery; Heidi Fancher; Helen Cheng; Michael Rosenblum; Mark van der Laan; Nicholas Jewell; James McIntyre
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

10.  Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention.

Authors:  Andrew Nunn; Sheena McCormack; Angela M Crook; Robert Pool; Clare Rutterford; Richard Hayes
Journal:  Trials       Date:  2009-10-27       Impact factor: 2.279

View more
  32 in total

1.  Targeted Pregnancy and Human Immunodeficiency Virus Prevention Risk-Reduction Counseling for Young Women: Lessons Learned from Biomedical Prevention Trials.

Authors:  Gita Ramjee; Reshmi Dassaye; Tarylee Reddy; Handan Wand
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

2.  Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.

Authors:  Lynette J Menezes; Ubin Pokharel; Staci L Sudenga; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim van der Loeff; Louvina E van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano
Journal:  Sex Transm Infect       Date:  2017-05-10       Impact factor: 3.519

3.  Detection of metronidazole resistance in Trichomonas vaginalis using uncultured vaginal swabs.

Authors:  Bongekile Ngobese; Ravesh Singh; Khine Swe Swe- Han; Partson Tinarwo; Nonkululeko Mabaso; Nathlee S Abbai
Journal:  Parasitol Res       Date:  2022-06-03       Impact factor: 2.383

4.  Significant Associations between Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Human Immunodeficiency Virus-Infected Pregnant Women.

Authors:  Bongekile Ngobese; Khine Swe Swe-Han; Partson Tinarwo; Nathlee S Abbai
Journal:  Infect Dis Obstet Gynecol       Date:  2022-06-17

5.  Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa.

Authors:  Lisa M Noguchi; Jeanne M Marrazzo; Barbara Richardson; Sharon L Hillier; Jennifer E Balkus; Thesla Palanee-Phillips; Gonasagrie Nair; Ravindre Panchia; Jeanna Piper; Kailazarid Gomez; Gita Ramjee; Z Mike Chirenje
Journal:  Front Reprod Health       Date:  2021-07-16

6.  An Update on the Global Epidemiology of Syphilis.

Authors:  Noah Kojima; Jeffrey D Klausner
Journal:  Curr Epidemiol Rep       Date:  2018-02-19

7.  Individual and Population Level Impact of Key HIV Risk Factors on HIV Incidence Rates in Durban, South Africa.

Authors:  Gita Ramjee; Suri Moonsamy; Nathlee Samantha Abbai; Handan Wand
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

8.  Incident HIV during pregnancy and early postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa.

Authors:  Terusha Chetty; Alain Vandormael; Claire Thorne; Anna Coutsoudis
Journal:  BMC Pregnancy Childbirth       Date:  2017-07-26       Impact factor: 3.007

9.  Prevalence and risk factors associated with sexually transmitted infections (STIs) among women of reproductive age in Swaziland.

Authors:  Themba G Ginindza; Cristina D Stefan; Joyce M Tsoka-Gwegweni; Xolisile Dlamini; Pauline E Jolly; Elisabete Weiderpass; Nathalie Broutet; Benn Sartorius
Journal:  Infect Agent Cancer       Date:  2017-05-25       Impact factor: 2.965

10.  Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries.

Authors:  Nigel J Garrett; Farzana Osman; Bhavna Maharaj; Nivashnee Naicker; Andrew Gibbs; Emily Norman; Natasha Samsunder; Hope Ngobese; Nireshni Mitchev; Ravesh Singh; Salim S Abdool Karim; Ayesha B M Kharsany; Koleka Mlisana; Anne Rompalo; Adrian Mindel
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.